Pembrolizumab and Ultrasound for Head and Neck Cancer
This study is testing a new way to deliver Pembrolizumab, a type of immunotherapy, for people with recurrent or metastatic (spread to other parts of the body) head and neck cancer that is HPV-negative. You would receive Pembrolizumab intravenously (into a vein) along with Definity, a special liquid that helps ultrasound work better. Then, ultrasound will be used on your tumor to help Pembrolizumab reach it more effectively. The main goal of this study is to see if this treatment approach is possible and if at least 80% of the 6 participants can complete all planned treatments. To join, your cancer must have a CPS score greater than 1, which is a measure of a specific biomarker (PD-1). The study status is currently unclear.
- Study design
- This is an interventional study that plans to enroll 6 participants. It is a feasibility trial, meaning it aims to see if the treatment approach is practical.
- What's involved
- You would receive up to 3 cycles of Pembrolizumab and Definity infusions, given three weeks apart. After each infusion, ultrasound will be applied to your tumor site.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will have a 3-month safety follow-up after your last treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joseph M Curry, MD · PRINCIPAL_INVESTIGATOR · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Number of Participants who complete all planned treatment cyclesUp to 9 weeks
The number of participants who completed trial procedures among at least 80 percent of patients, among patients with recurrent or metastatic head and neck squamous cell carcinoma.